Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?Zacks Investment Research • 01/10/25
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to BuyZacks Investment Research • 01/09/25
Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'Investopedia • 01/08/25
Novo Nordisk expands AI partnership with Valo Health for development of obesity drugsReuters • 01/08/25
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck DealsBenzinga • 01/08/25
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli LillyThe Motley Fool • 01/08/25
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pactMarket Watch • 01/08/25
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseasesGlobeNewsWire • 01/08/25
Trump's Danish Tariff Threat Means News Uncertainty for Ozempic Drugmaker Novo NordiskBarrons • 01/07/25
Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50MGeekWire • 01/07/25
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a BetZacks Investment Research • 01/07/25
Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical ConcernsBenzinga • 01/07/25
Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More PotentialSeeking Alpha • 01/06/25
4-Factor Dividend Growth Strategy - Cold Winter Air Creeps Into The PortfolioSeeking Alpha • 01/04/25